FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964045421> ?p ?o ?g. }

• W2964045421 endingPage "1022" @default.
• W2964045421 startingPage "1011" @default.
• W2964045421 abstract "Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therapy (epoetin alfa) for the treatment of anemia in patients undergoing dialysis.In a trial conducted in China, we randomly assigned (in a 2:1 ratio) patients who had been undergoing dialysis and erythropoiesis-stimulating agent therapy with epoetin alfa for at least 6 weeks to receive roxadustat or epoetin alfa three times per week for 26 weeks. Parenteral iron was withheld except as rescue therapy. The primary end point was the mean change in hemoglobin level from baseline to the average level during weeks 23 through 27. Noninferiority of roxadustat would be established if the lower boundary of the two-sided 95% confidence interval for the difference between the values in the roxadustat group and epoetin alfa group was greater than or equal to -1.0 g per deciliter. Patients in each group had doses adjusted to reach a hemoglobin level of 10.0 to 12.0 g per deciliter. Safety was assessed by analysis of adverse events and clinical laboratory values.A total of 305 patients underwent randomization (204 in the roxadustat group and 101 in the epoetin alfa group), and 256 patients (162 and 94, respectively) completed the 26-week treatment period. The mean baseline hemoglobin level was 10.4 g per deciliter. Roxadustat led to a numerically greater mean (±SD) change in hemoglobin level from baseline to weeks 23 through 27 (0.7±1.1 g per deciliter) than epoetin alfa (0.5±1.0 g per deciliter) and was statistically noninferior (difference, 0.2±1.2 g per deciliter; 95% confidence interval [CI], -0.02 to 0.5). As compared with epoetin alfa, roxadustat increased the transferrin level (difference, 0.43 g per liter; 95% CI, 0.32 to 0.53), maintained the serum iron level (difference, 25 μg per deciliter; 95% CI, 17 to 33), and attenuated decreases in the transferrin saturation (difference, 4.2 percentage points; 95% CI, 1.5 to 6.9). At week 27, the decrease in total cholesterol was greater with roxadustat than with epoetin alfa (difference, -22 mg per deciliter; 95% CI, -29 to -16), as was the decrease in low-density lipoprotein cholesterol (difference, -18 mg per deciliter; 95% CI, -23 to -13). Roxadustat was associated with a mean reduction in hepcidin of 30.2 ng per milliliter (95% CI, -64.8 to -13.6), as compared with 2.3 ng per milliliter (95% CI, -51.6 to 6.2) in the epoetin alfa group. Hyperkalemia and upper respiratory infection occurred at a higher frequency in the roxadustat group, and hypertension occurred at a higher frequency in the epoetin alfa group.Oral roxadustat was noninferior to parenteral epoetin alfa as therapy for anemia in Chinese patients undergoing dialysis. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652806.)." @default.
• W2964045421 created "2019-07-30" @default.
• W2964045421 creator A5000229414 @default.
• W2964045421 creator A5001094449 @default.
• W2964045421 creator A5002674172 @default.
• W2964045421 creator A5002818639 @default.
• W2964045421 creator A5004318775 @default.
• W2964045421 creator A5007054845 @default.
• W2964045421 creator A5015575105 @default.
• W2964045421 creator A5016423085 @default.
• W2964045421 creator A5028863621 @default.
• W2964045421 creator A5030478269 @default.
• W2964045421 creator A5033144266 @default.
• W2964045421 creator A5037220425 @default.
• W2964045421 creator A5043911240 @default.
• W2964045421 creator A5048018294 @default.
• W2964045421 creator A5051574760 @default.
• W2964045421 creator A5058396165 @default.
• W2964045421 creator A5064478014 @default.
• W2964045421 creator A5065987768 @default.
• W2964045421 creator A5069619201 @default.
• W2964045421 creator A5076894195 @default.
• W2964045421 creator A5077679832 @default.
• W2964045421 creator A5079226794 @default.
• W2964045421 creator A5085657697 @default.
• W2964045421 date "2019-09-12" @default.
• W2964045421 modified "2023-10-17" @default.
• W2964045421 title "Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis" @default.
• W2964045421 cites W1984393349 @default.
• W2964045421 cites W1992177979 @default.
• W2964045421 cites W2005973637 @default.
• W2964045421 cites W2020960798 @default.
• W2964045421 cites W2042960850 @default.
• W2964045421 cites W2046224330 @default.
• W2964045421 cites W2050442786 @default.
• W2964045421 cites W2056532614 @default.
• W2964045421 cites W2073292880 @default.
• W2964045421 cites W2085609942 @default.
• W2964045421 cites W2089264894 @default.
• W2964045421 cites W2098124630 @default.
• W2964045421 cites W2098824669 @default.
• W2964045421 cites W2104810766 @default.
• W2964045421 cites W2116991069 @default.
• W2964045421 cites W2122633654 @default.
• W2964045421 cites W2124116160 @default.
• W2964045421 cites W2136732413 @default.
• W2964045421 cites W2159817369 @default.
• W2964045421 cites W2171811563 @default.
• W2964045421 cites W2174706993 @default.
• W2964045421 cites W2178101235 @default.
• W2964045421 cites W2272875085 @default.
• W2964045421 cites W2331089096 @default.
• W2964045421 cites W2339445416 @default.
• W2964045421 cites W2520991089 @default.
• W2964045421 cites W2599499085 @default.
• W2964045421 cites W2761854305 @default.
• W2964045421 cites W2963534431 @default.
• W2964045421 cites W4300187280 @default.
• W2964045421 cites W3149132779 @default.
• W2964045421 doi "https://doi.org/10.1056/nejmoa1901713" @default.
• W2964045421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31340116" @default.
• W2964045421 hasPublicationYear "2019" @default.
• W2964045421 type Work @default.
• W2964045421 sameAs 2964045421 @default.
• W2964045421 citedByCount "366" @default.
• W2964045421 countsByYear W29640454212019 @default.
• W2964045421 countsByYear W29640454212020 @default.
• W2964045421 countsByYear W29640454212021 @default.
• W2964045421 countsByYear W29640454212022 @default.
• W2964045421 countsByYear W29640454212023 @default.
• W2964045421 crossrefType "journal-article" @default.
• W2964045421 hasAuthorship W2964045421A5000229414 @default.
• W2964045421 hasAuthorship W2964045421A5001094449 @default.
• W2964045421 hasAuthorship W2964045421A5002674172 @default.
• W2964045421 hasAuthorship W2964045421A5002818639 @default.
• W2964045421 hasAuthorship W2964045421A5004318775 @default.
• W2964045421 hasAuthorship W2964045421A5007054845 @default.
• W2964045421 hasAuthorship W2964045421A5015575105 @default.
• W2964045421 hasAuthorship W2964045421A5016423085 @default.
• W2964045421 hasAuthorship W2964045421A5028863621 @default.
• W2964045421 hasAuthorship W2964045421A5030478269 @default.
• W2964045421 hasAuthorship W2964045421A5033144266 @default.
• W2964045421 hasAuthorship W2964045421A5037220425 @default.
• W2964045421 hasAuthorship W2964045421A5043911240 @default.
• W2964045421 hasAuthorship W2964045421A5048018294 @default.
• W2964045421 hasAuthorship W2964045421A5051574760 @default.
• W2964045421 hasAuthorship W2964045421A5058396165 @default.
• W2964045421 hasAuthorship W2964045421A5064478014 @default.
• W2964045421 hasAuthorship W2964045421A5065987768 @default.
• W2964045421 hasAuthorship W2964045421A5069619201 @default.
• W2964045421 hasAuthorship W2964045421A5076894195 @default.
• W2964045421 hasAuthorship W2964045421A5077679832 @default.
• W2964045421 hasAuthorship W2964045421A5079226794 @default.
• W2964045421 hasAuthorship W2964045421A5085657697 @default.
• W2964045421 hasBestOaLocation W29640454211 @default.
• W2964045421 hasConcept C126322002 @default.
• W2964045421 hasConcept C141071460 @default.
• W2964045421 hasConcept C168563851 @default.

• next